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The Anticancer Natural Product Pironetin
Selectively Targets Lys352 of -Tubulin
Lys352 of -tubulin and inhibits the interaction of tu-
bulin heterodimers.
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1Antibiotics Laboratory
Drugs that interact with microtubules are expected to2 Biomolecular Characterization Team
be useful not only as antitumor agents, but also as toolsRIKEN Discovery Research Institute
for understanding a wide variety of the cellular functions2-1 Hirosawa
of microtubules, such as mitosis, cell signaling, and mo-Wako-shi, Saitama 351-0198
tility in eukaryotes. Microtubule inhibitors displayingJapan
great structural diversity have been identified and well3 Department of Applied Biological Chemistry
characterized because of their extensive application inGraduate School of Agricultural and Life Science
medicinal and basic research. Paclitaxel and vinblastineThe University of Tokyo
are clinically used as anticancer drugs. They bind to1-1-1 Yayoi
different sites of -tubulin and show opposite effectsBunkyo-ku, Tokyo 113-8657
in vitro: paclitaxel induces microtubule bundling andJapan
vinblastine induces microtubule disassembly [1, 2].4 Chemistry Laboratory
Epothilones bind the paclitaxel binding site on -tubulinHanno Research Center
and stabilize microtubule filaments [3, 4], and clinicalTaiho Pharmaceutical Co., Ltd.
trials using several derivatives are undergoing [5]. The1-27 Misugidai
other microtubule inhibitors, for example, TZT-1027,Hanno, Saitama 357-8527
2-methoxyestradiol, and taxane derivatives, are in clini-Japan
cal development [6, 7]. We have reported that trypro-5 Research and Development Division
statin A inhibited microtubule-associated protein-depen-Nippon Kayaku Co., Ltd.
dent tubulin assembly by binding to tubulin at binding3-31-12 Shimo
sites different from those used by colchicine and vin-Kita-ku, Tokyo 115-8588
blastine [8–10]. However, in most of the cases, micro-Japan
tubule-directed drugs bound to -tubulin with a few
exceptions (dinitroaniline herbicides and B-ring of col-
chicines) [11–13].
Summary Some bioactive chemicals containing ,-unsatu-
rated lactone are known to bind to proteins. For exam-
Pironetin is a potent inhibitor of tubulin assembly and ple, cyclopentenone prostaglandins bind to Cys179 of
arrests cell cycle progression in M phase. Analyses IKK and inhibit inflammatory reactions by decreasing
of its structure-activity relationships suggested that IKK complex kinase activity [14]. In addition to endoge-
pironetin covalently binds tubulin. To determine the nous compounds, several chemicals covalently bind to
binding site of pironetin, we synthesized biotinylated their own target proteins by Michael addition. Lepto-
pironetin, which inhibited tubulin assembly both in vitro mycin B, a nuclear export inhibitor, binds to Cys529 of
and in situ. The biotinylated pironetin selectively and CRM1/exportin 1 and inhibits protein export from nuclei
covalently bound with tubulin. Partial digestion of bio- [15–19]. It is suggested that the PP2A-specific inhibitor
tinylated pironetin-treated tubulin by several prote- fostriecin binds to Cys269 of PP2A and inhibits its phos-
ases revealed that the binding site is the C-terminal phatase activity [20, 21]. Recently, we also reported that
portion of -tubulin. By systematic alanine scanning, isoavenaciolide binds to the catalytic center cysteine of
the pironetin binding site was determined to be Lys352 dual-specificity phosphatase VHR and inhibits its phos-
of -tubulin. Lys352 is located at the entrance of a phatase activity [22, 23]. Michael addition is a reaction
small pocket of -tubulin, and this pocket faces the that is likely to be nonspecific to biological nucleophiles
-tubulin of the next dimer. This is the first compound such as cysteine, but it has been shown that most of
that covalently binds to the  subunit of tubulin and the chemicals listed above are site/protein specific.
Their high specificity is thought to be due to structural
elements in addition to the lactone moiety.*Correspondence: hisyo@riken.jp
Previously, we reported that pironetin (1a in Figure 1)6 Present address: Technical Research Center, T. Hasegawa Co.,
Ltd., 335 Kariyado, Nakahara-ku, Kawasaki-shi, Kanagawa 211- and its derivatives are M phase inhibitors and exhibit
0022, Japan. antitumor activity by apoptosis induction via microtu-
7 Present address: Department of Pharmaceutics and Biopharma- bule disassembly [24, 25]. Pironetin inhibits tubulin bind-
ceutics, Showa Pharmaceutical University, 3-3165 Machida, Tokyo ing of radiolabeled vinblastine, and the affinity of piro-
194-8543, Japan.
netin to tubulin is stronger than that of vinblastine.8 Present address: Large Scale Protein Production Team, RIKEN
Furthermore, pironetin has a unique structure containingHarima Institute, 1-1-1 Kouto, Mikazuki, Sayo, Hyogo 679-5148,
Japan. only one pyran residue and an alkyl chain, which is
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Figure 2. The Effects of Biotinylated Pironetin on the Microtubule
Network and Cell Cycle Progression in 3Y1 Cells
(A and B) Microtubule network in 3Y1 cells treated with (B) or without
(A) 1 g/ml biotinylated pironetin for 18 hr. Microtubules were ob-
served under a fluorescence microscopy.
Figure 1. Structure of Pironetin and Its Derivatives (C and D) Distribution of DNA content in asynchronous culture of
3Y1 cells treated with (D) or without (C) 1g/ml biotinylated pironetinShown are pironetin (1a) and the derivatives 2-4a, b, and 5.
for 18 hr.
simpler than the structure of other M phase inhibitors. though the concentrations were higher than that of natu-
These features of pironetin, which are distinct from ral pironetin (20 nM). The differences of effective con-
known tubulin binding agents, suggest that it is possible centrations between pironetin and biotinylated pironetin
to create a new drug useful for cancer therapy from was not observed in vitro microtubule polymerization
pironetin as a lead compound. From the analyses of assay (data not shown), suggesting that the permeability
structure-activity relationships, it was revealed that of biotinylated pironetin is much lower than that of piro-
,-unsaturated lactone is important for microtubule in- netin.
hibition [26]. This characteristic strongly suggests that We next investigated whether or not biotinylated piro-
pironetin covalently binds to tubulin by Michael addition. netin covalently modifies tubulins in situ. 3Y1 cells were
In this paper, we determined the binding site of piro- cultured with 1 M biotinylated pironetin for 4 hr, the
netin to be the Lys352 of -tubulin by using biotinylated biotin-containing complexes were isolated by streptavi-
analogs as probes. Pironetin is the first compound din-conjugated agarose beads, and the bound proteins
shown to bind to -tubulin directly. The binding site is were analyzed by SDS-PAGE followed by Western blot-
located on the surface of -tubulin facing the -tubulin ting (Figure 3). Western blotting using streptavidin-
of the next heterodimer, which corresponds to the vin- horseradish peroxidase showed a number of biotinyl-
blastine binding site. ated proteins in both the control cells and biotinylated
pironetin-treated cells. However, the sample containing
biotinylated pironetin revealed one additional 50 kDaResults
protein (Figure 3A, lane 1, arrow). This band was not
detected when the sample was treated with inactivePironetin Covalently Binds to Tubulin
In Vitro and In Situ biotinylated pironetin derivatives or biotin alone (Figure
1, 2-4b, and Figure 3A, lanes 2–4, data not shown). TheWe previously reported that a 2,3-dihydro derivative of
pironetin, with a saturated lactone moiety, was dramati- binding was also blocked when 20 nM of pironetin was
added as a competitor to the cell culture 2 hr beforecally weaker in microtubule disassembly activity and
cell cycle arrest in M phase. These results suggested the biotinylated pironetin addition (Figure 3B, lane 2).
But the binding was not blocked when the cell culturethat pironetin inhibits tubulin assembly through covalent
binding. To investigate whether or not pironetin binds was treated with inactive derivatives 2a (Figure 3B, lane
3). These results indicate that pironetin specifically andcovalently, we synthesized biotinylated pironetin (1b in
Figure 1). Biotinylated pironetin induced microtubule covalently binds to the 50 kDa cellular protein.
Pironetin is a potent microtubule inhibitor and inhibitsdisassembly in proliferating 3Y1 cells and cell cycle ar-
rest in M phase at the concentration of 1 M (Figure 2). polymerization of purified tubulin in vitro. Since tubulins
consist of heterodimers of - and -tubulins with 50The effects of biotinylated pironetin and natural piro-
netin were indistinguishable and no other effect was kDa molecular weight, the 50 kDa protein detected by
treatment with biotinylated pironetin was thought to beobserved in biotinylated pironetin-treated cells, al-
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Figure 3. Pironetin Covalently Binds to Tubulin In Situ and In Vitro
(A) Rat normal fibroblast 3Y1 cells were treated with biotinylated
pironetin (1b) and inactive biotinylated derivatives (2-4b). A single 50
kDa protein (corresponding to tubulin; arrow) emerged by treatment
with biotinylated pironetin but not biotinylated inactive pironetin.
Asterisks indicate intrinsic biotin binding proteins.
(B) Protein binding of biotinylated pironetin in the presence of piro-
netin competitor (1a), but not inactive pironetin (2a) in situ (left) and
in vitro (right).
Figure 4. Determination of Pironetin Binding Site
(A) Biotinylated tubulin and partially digested peptides are indicated
by an asterisk and arrows, respectively. ST, subtilisin-BPN; CT, chy-
- or -tubulin. To determine whether or not the biotinyl- motrypsin; ET, elastase.
ated pironetin was bound to tubulin, we tested the (B) The alignments of biotinylated pironetin bound peptides. The
obtained sequences were aligned with chicken -tubulin (under-in vitro binding using purified bovine tubulin. Purified
lined). Putative pironetin binding residues, i.e., all cysteines andtubulin protein was incubated with biotinylated pironetin
lysines between the 270th to 360th residues, are shown as squares.in combination with or without competitor. Biotinylated
(C) Pironetin failed to bind Lys352Ala mutated tubulin. All cysteine
pironetin covalently bound to purified tubulin, and its and lysine residues between the 270th and 370th residues of -tubulin
binding was retarded by addition of competitor (Figure were changed to alanine and translated in vitro using reticulocyte
3B, lanes 4 and 5). Together with the previous biological lysate. After incubation of 35S-labeled translated mutant tubulins
with biotinylated pironetin, biotinylated tubulins were precipitatedresults that pironetin inhibits tubulin assembly in situ
by the immobilized streptavidin matrix. Bar show mean  deviationand in vitro [25], this finding led us to conclude that
obtained from two independent experiments.pironetin binds to tubulin heterodimers covalently.
Pironetin Binds to Lys352 of -Tubulin din-HRP (Figure 4A). There were several biotinylated
peptides, and the N-terminal amino acid sequences ofDuring the course of the binding assay, we noticed that
the binding of pironetin to tubulin was labile under acidic these biotinylated peptides—19 kDa (subtilisin-BPN), 22
kDa (chymotrypsin), 24 kDa (elastase), and 17 kDaand basic pH conditions (pH  4.5 and  8.0, data
not shown). These results suggest that retro-Michael (Lys-C)—were determined. These sequence corre-
sponded to L259VPYPRIHFPLATY272 (subtilisin-BPN),addition readily occurs under nonphysiological pH con-
ditions. Furthermore, this characteristic made it difficult L259VPYPRIH266 (chymotrypsin), E254FQT257 (elastase), and
S160KLEFSIYPA169 (Lys-C) of chick -tubulin (Figure 4B).to determine the binding site by LC-MS, because an
acidic condition is usually used to separate the prote- According to the size of Lys-C-treated peptide fragment,
the pironetin binding site was suggested from the 270thase-digested peptides. Therefore, we first used partial
protease digestion to determine the region of the binding and 370th residue of -tubulin.
As the sulfhydryl group of cysteine residues or thesite. Biotinylated pironetin-treated tubulin was partially
digested with several proteases, and the biotinylated -amino group of lysine residues are expected as a bind-
ing site of pironetin, we used alanine scanning of bothpironetin bound peptides were separated by Tris/Tricine
SDS-PAGE followed by Western blotting with Streptavi- cysteine and lysine to determine the pironetin binding
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site. All cysteine and lysine residues between the 270th netin binding with Lys352 and Asn258 disrupts the hy-
drogen network among Glu254, Lys352, and Asn258 andand 360th residue of human -tubulin were changed to
alanine by PCR mutagenesis. All mutants functioned then influences the GTP hydrolysis activity of Glu254.
To confirm the binding model of pironetin andin situ as judged from the incorporation of GFP-fusion
mutant proteins into the microtubule network by trans- -tubulin, we made an -tubulin mutant, Asn258Ala, and
tested the binding efficiency by in vitro translation/fection to HeLa cells (data not shown). Next, we used
an in vitro translation system with rabbit reticulocyte binding assay. As expected, the binding efficiency of
Lys352Ala and Asn258Ala were decreased to 20% andlysate to determine the binding site. 35S-labeled mutant
tubulins were synthesized by in vitro transcription/trans- 75%, respectively (Figure 5C). These results reinforce
the binding model and strongly suggest that pironetinlation and tested for their ability to bind biotinylated
pironetin. As shown in Figure 4C, 35S-labeled wild-type covalently binds Lys352 on -tubulin.
tubulin was precipitated with the immobilized streptavi-
din matrix in a biotinylated pironetin-dependent manner
Discussion(Figure 4C, left). All cysteine mutants were precipitated
with biotinylated pironetin, but it took overnight incuba-
We previously reported that pironetin is a potent inhibi-tion to precipitate the Cys315Ala and Cys316Ala mu-
tor of cell cycle progression at the M phase and showstants (see Discussion). In contrast, one of the lysine
antitumor activity against a murine tumor cell line, P388mutants, Lys352Ala, failed to precipitate with drug irre-
leukemia, transplanted in mice [24]. Pironetin has aspective of the incubation time (Figure 4C, right). These
unique structure containing only one pyran residue andresults strongly suggest that pironetin binds to Lys352
an alkyl chain, which is simpler than the structures ofof -tubulin by Michael addition. The observation that
other M phase inhibitors. To create a new drug usefulpironetin binds to -tubulin is unexpected, because in
for cancer therapy from pironetin as a lead compound,most of the cases in which the binding site has been
we here investigated the pironetin binding site on tu-determined, the known tubulin binding compounds bind
bulin. According to the structure-activity relationshipto -tubulin.
analyses, we speculated that pironetin covalently binds
tubulin by Michael addition via its ,-unsaturated
-lactone [26]. To determine whether pironetin bindsPironetin Binding Model
To confirm that the pironetin binding site was Lys352 tubulin, we synthesized biotinylated pironetin (Figure
1, 1b). The biotinylated pironetin (1b), which inhibitedof -tubulin, we simulated a binding model of tubulin
with pironetin using the tubulin structure data obtained tubulin assembly both in vitro and in situ, covalently
bound with tubulin, and its binding was inhibited byfrom electron crystallography [27, 28]. Lys352 of
-tubulin is on the strand of  sheet 9 and located in natural pironetin (1a) (Figure 3). We could not exclude
the possibility that biotinylated pironetin binds the otherthe entrance of a small cavity. Cys315 and Cys316 are
located on neighboring  sheet 8 and are not on the protein with undetectable level. The finding that inactive
pironetin derivatives failed to bind tubulin in situ sug-surface of -tubulin but just behind Lys352, meaning
these residues are not pironetin binding sites. gested that covalent binding is important for pironetin
to inhibit tubulin polymerization.The 3D structure of the complex of tubulin and piro-
netin was estimated through energy minimization and Although it is known that the compounds that bind to
their target proteins by Michael addition bind to thedynamics simulation. The initial structure was generated
by bonding carbon atom at the 3-position of pironetin sulfhydryl group of cysteine residues or -amino group
of lysine residues [30], most compounds bind to theto the -amino group of Lys352 of -tubulin manually
based on the putative binding site and the interaction sulfhydryl group of cysteine residues. However, we as-
sumed that pironetin binds to the -amino group of ly-energy in a vacuum using the computer program. The
3D structure of the tubulin molecule based on electron- sine, because tubulin binding by pironetin is labile under
acidic and basic pH conditions. To determine the bind-ray crystallography was used as the initial structure. The
results are shown in Figures 5A and 5B. There are three ing site of pironetin, we used an in vitro translation sys-
tem with rabbit reticulocyte lysates, because it was re-hydrogen bonds: an oxygen atom of the 9-methoxy moi-
ety of pironetin forms both intramolecular and intermo- ported that this in vitro system contains a chaperonine
system needed for correct folding of tubulin [31, 32].lecular hydrogen bonds with the hydrogen atom of the
7-hydroxy moiety of pironetin (1.87 A˚) and the amine Partial proteolytic analyses of biotinylated pironetin
bound peptides, followed by systematic alanine scan-moiety of Asn258 (2.05 A˚), respectively. The methyl and
methoxy moiety of pironetin is fitted quite well into the ning of both cysteine and lysine residues, strongly sug-
gested that Lys352 of -tubulin is the pironetin bindingcavity formed with  helixes 8/10 and  sheets 8/9, and
7-hydroxyl moiety of pironetin forms both intramolecular site (Figures 4 and 5). This is surprising, because the
reactivity of the -amino group of lysine is quite lowand intermolecular hydrogen bonds with the pyran ring
and Asn258 of -tubulin, respectively. Asn258 locates compared with that of the sulfhydryl group of cysteine.
The in silico analysis of the pironetin-tubulin complexon the  helix 8, the same helix Glu254 locates on, and
it is speculated that Asn258 forms a hydrogen bond suggested that  helixes 8/10 and  sheet 8 form a
cavity that fits pironetin well (Figure 5B). This bindingnetwork with Glu254 via Lys352. Glu254, a residue con-
served in essentially all -tubulins, is in an ideal position model is supported by the following results.
First, pironetin binding to the Cys315Ala- and Cys-to be involved in the hydrolysis of GTP of the E site in
-tubulin [29]. This binding model suggests that piro- 316Ala-mutated tubulins was much slower than the
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Figure 5. Proposed Binding Model of -Tubu-
lin-Pironetin Complex
(A) Secondary structure around the pironetin
binding site on -tubulin and binding model.
(B) The white dashed lines show possible hy-
drogen bonds, and the yellow arrowhead
shows the -amino moiety of the Lys352 at-
tack site of pironetin.
(C) Pironetin did not bind to N258A and K352A
mutant -tubulins efficiently.
binding to the wild-type and the other mutants (Figure vinblastine? Lys352 is located on the entrance of a small
pocket of -tubulin, and this pocket is on the interdimer4, data not shown). Since these residues locate just
behind Lys352, we speculate that the mutations fail to surface facing the GTP binding domain of the -tubulin
of the next dimer (Figure 6, Lys352 is enclosed with redposition Lys352 correctly.
Second, pironetin binding to Asn258Ala-mutated circle). On the other hand, the vinca alkaloid binding site
is speculated to locate to residues 177–215 in -tubulin-tubulin was decreased to 75% compared with that to
wild-type -tubulin. Although Asn258 seems to be the [33], the site near the GTP binding site, and this region
is on the interdimer interface of the -tubulin side (Figurekey residue forming hydrogen bonds with pironetin in
this model, the effects on the binding were low com- 6, yellow circle) [1, 2]. So, the pironetin binding site on
-tubulin gets closer to the vinblastine binding site onpared with those by the binding site mutation Lys352Ala.
This is because pironetin fits the cavity so well that the -tubulin when two tubulin heterodimers polymerize
(Figure 6). These structural data prompt us to hypothe-contribution of the water repulsive force is much higher
than that of the hydrogen bond formation on the de- size that pironetin bound -tubulin can bind to microtu-
bules and cover the vinca alkaloid binding site oncrease enthalpy.
Third, yeast cells harboring tub1-K353A (correspond- -tubulin irrespective of direct or indirect interaction
with pironetin, since vinblastine would be accessible toing to Lys352Ala -tubulin) showed pironetin resistance
(see Supplemental Data at http://www.chembiol.com/ the vinca alkaloid binding site on -tubulin if the piro-
netin bound -tubulin lost binding activity. Otherwise,cgi/content/full/11/6/799/DC1). These results strongly
suggest that the binding site of pironetin on -tubulin both pironetin and vinca alkaloid binding sites might
be formed when tubulin heterodimers polymerize. Theis Lys352.
We previously reported that pironetin decreased the reports that Lys350 of -tubulin, at analogous positions
on different subunits, is involved in colchicines bindingtubulin binding of [3H]vinblastine and slightly increased
the binding of [3H]colchicine, so we speculated that piro- [34] and that colchicine B ring interacts with -tubulin
in addition to A/C ring interacts with -tubulin [13] raisenetin binds the vinca alkaloid binding site on -tubulin
[25]. However, we have to correct this conclusion here, the possibility that the colchicine and pironetin/vinca
alkaloid binding sites might be similar sites but at differ-because we obtained evidence that Lys352 of -tubulin
is the pironetin binding site. Although pironetin binds ent subunit interfaces. Because colchicine stimulated
[3H]vinblastine binding and pironetin/vinblastine stim--tubulin, how does pironetin inhibit tubulin binding of
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[29]. The influences of pironetin binding upon both
GTPase activity on the E site and interdimer interactions
remain to be determined.
In conclusion, we determined the pironetin binding
site to be Lys352 on -tubulin. Furthermore, the data
demonstrate that the natural product pironetin pos-
sesses the novel property of highly site-selective bind-
ing to the -amino moiety of lysine by Michael addition.
These data have important implications for the design
of molecularly targeted small molecules.
Significance
Many inhibitors for microtubule functions have been
reported, for example, vinca alkaloid, paclitaxel, epothi-
lones, and so on. As far as we know, all the natural
compounds inhibiting tubulin polymerization/depoly-
merization act on -tubulin. In this paper, we found that
pironetin, a potent inhibitor of tubulin assembly, cova-
lently binds -tubulin. This is the first compound that
covalently binds to -tubulin. We also identified that
pironetin binding site is Lys352 of -tubulin. Since it
is known that most of the compounds containing
,-unsaturated lactone covalently bind to sulfhydryl
group of cysteine residue, pironetin is a unique com-
pound, which binds specific lysine residue on -tubu-
lin. These features of pironetin, which are distinct from
known tubulin binding agents, suggest that it is possi-
ble to create a new drug useful for cancer therapy
from pironetin as a lead compound.
Experimental Procedures
Synthesis of Biotinylated Pironetin and Its Derivatives
Pironetin (1a in Figure 1) was purified from Streptomyces sp.
NK10958 [35]. Inactive pironetin derivatives (2-4a) were synthesized
as previously reported [26]. Biotinylated pironetin (1b) was synthe-Figure 6. The Pironetin Binding Site on -Tubulin Comes in Close
sized by two-step reaction from 1a. A mixture of 1a (20.0 mg, 0.062Proximity to the vinca Alkaloid Binding Site and the GTPase Site on
mmol), N-Boc--aminocapronic acid (21.4 mg, 0.093 mmol),-Tubulin by Interdimer Polymerization
4-(dimethylamino)pyridine (0.5 mg), n-hexane (5 ml), and N.N-
The interdimer interfaces of both - and -tubulin are shown. Red dicyclohexylcarbodiimide (19.1 mg, 0.093 mmol) was stirred at room
circle: the pironetin binding site on -tubulin. Yellow circle: the vinca temperature for 12 hr. The mixture was filtered through a celite pad
alkaloid binding site on -tubulin. and then concentrated in vacuo. The residue was chromatographed
on silica gel (10 g) eluted with n-hexane/ethylacetate (5:1–3:1)
to give 5 (19.6 mg). To a solution of 5 (3.5 mg, 0.0065 mmol) in
ulated [3H]colchicines binding on tubulin [25], these dichloromethane (1 ml) was added trifluoroacetic acid (0.5 ml). After
being stirred for 1 hr, the mixture was concentrated in vacuo andcompounds might induce the similar conformational
the residue was dissolved in dimethylformamide (1 ml). After addingchanges on binding and neighboring subunit. These
triethylamine (30 l, 0.22 mmol) and succinimidyl-5-(biotinamido)possibilities should be elucidated by several methods.
hexanoate (EZ-Link NHS-LC-Biotin; Pierce, Rockford, IL), the mix-
How does pironetin inhibit microtubule polymeriza- ture was stirred at 0	C for 1 hr and concentrated in vacuo. The
tion? Despite the fact that the binding subunit is different residue was dissolved in chloroform (1 ml) and methanol (20 l),
from that of vinblastine, the effects of pironetin on vin- stirred for 10 min, concentrated in vacuo, and purified by reverse-
phase preparative thin layer chromatography (H2O/methanol 
 1:4)blastine and colchicine binding to tubulin were similar
to give biotinylated pironetin (1b, 4.8 mg). The other biotinylatedto that of vinblastine. These results might suggest that
derivatives of inactive pironetin (2-4b) were synthesized by the samepironetin induces conformational changes of -tubulin
scheme. The structures of the compounds were confirmed by 1H
by interdimer or intradimer interaction and that pironetin NMR using a BRUKER AC300 spectrometer (Bruker Analytische
and vinblastine inhibit microtubule polymerization by Messtechnik GmbH, Rheinstetten, Germany).
the same mechanism, such as by changing GTPase
activity on the E site. Indeed, Lys352 locates close to Cell Culture, Flow Cytometry, Immunofluorescence
Procedure, and TransfectionGlu254, which is a residue conserved in essentially all
3Y1 cells (rat normal fibroblasts) and HeLa cells were cultured in-tubulins, and is in an ideal position to be involved in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetalthe hydrolysis of GTP of the E site in -tubulin. Further-
bovine serum in a humidified atmosphere containing 5% CO2. Flowmore, the tub1-K353A in yeast did not complement the cytometry and an immunofluorescence procedure were then per-
deletion of -tubulin like tub1-E255A (corresponding to formed as described previously [9]. GFP-fused -tubulins (wild-type
and Ala-scanned mutants created as described below) were con-Glu254 of mammalian -tubulin) (Supplemental Data)
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structed with pEGFP-C1 (CLONTEC Laboratories, Inc., Palo Alto, sample buffer. The binding activities of mutant -tubulin were deter-
mined by autoradiography with BAS2500 (Fuji Film, Tokyo, Japan).CA). The gene was transfected into exponentially growing HeLa
cells with FuGENE 6 (Promega Corporation, Madison, WI), and GFP
signals were observed after 48 hr incubation with a cooled charge- Binding Model of the Tubulin-Pironetin Complex
coupled device (CCD) camera (Olympus PROVIS AX70; Olympus, The 3D structure of the complex of tubulin and pironetin molecules
Tokyo, Japan). was estimated through energy minimization. The initial structure
was generated by docking a pironetin molecule to an -tubulin
molecule manually based on the putative binding site and the inter-Preparation of Microtubules and Tubulin Protein
action energy in vacuo using the computer program QUANTA (Accel-Microtubule proteins were prepared from calf brain as described
rys Inc., San Diego, CA). The 3D structure of the -tubulin moleculepreviously [9]. Tubulin was further purified to remove microtubule-
based on electron crystallographic findings has already been re-associated proteins by phosphocellulose (P11; Whatman, Kent, UK)
ported and was used in the present study as the initial structure. Thecolumn chromatography of microtubule proteins.
extended structure was used as the initial structure of the pironetin
molecule. We used the program CHARMm 23.2 (Accelrys) for energyPironetin Binding Assay
minimization in vacuo under -carbon atom constraints using theTo investigate in situ binding, 3Y1 cells (2  107 cells) in culture
adopted-based Newton-Raphson method.were pretreated with 0.1% DMSO (control) or 100 nM of competitors
for 30 min and then incubated with 1 g of biotinylated pironetin
Supplemental Datafor 2 hr. After the cells had been lysed with RB (100 mM MES, 1 mM
A supplemental figure, showing the effects of pironetin, is availableEGTA, 0.5 mM MgCl2 [pH 6.7]) containing 1 mM PMSF and 0.1%
online at http://www.chembiol.com/cgi/content/full/11/6/799/DC1.NP-40, the supernatants were prepared by centrifugation. Twenty
microliters of streptavidin-agarose (EMD Biosciences, Inc., Darm-
stadt, Germany) were added to the lysates prepared from the cells Acknowledgments
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